Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

STOP2030

Financiado

STOP 2030: TOWARDS THE INTERRUPTION OF TRANSMISSION OF SOIL-TRANSMITTED HELMINTH...

STOP 2030: TOWARDS THE INTERRUPTION OF TRANSMISSION OF SOIL-TRANSMITTED HELMINTHS: PROMOTING IMPLEMENTATION OF RESEARCH RESULTS OF A FIXED-DOSE COMBINATION OF CO-FORMULATED IVERMECTIN AND AL Soil-Transmitted Helminths (STH) remain a significant public health problem with recognized obstacles for control and elimination with the current benzimidazole regimens in Mass Drug Administration (MDA) campaigns. Renewed targets... ver más

30/06/2026

LABORATORIOS LICON...

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

LABORATORIOS LICONSA Actividades propias de un laboratorio farmaceutico titular fabricante, comercializador exportador e importador de especialidades farmaceutic...

TRL 7-8 | 2M€

Ver 8 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-07

HORIZON-JU-GH-EDCTP3-2022-CALL1-01-01: Promoting implementation of researc... ExpectedOutcome:This topic aims at supporting activities that contribute to one or several of the ex...

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

8 Participantes

LABORATORIOS LICONSA

483.82K€ | Lider

GRL

369.15K€ | Participante

Bridges to Development

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RTI2018-093940-B-I00 DESARROLLO DE FARMACOS DIRIGIDOS A LA MITOCONDRIA Y ORGANULO... 194K€ Cerrado

STROGHAT Stop transmission of gambiense human African trypanosomiasis 4M€ Cerrado

DRUGSBUGS Improved therapies for soil transmitted helminthiases explo... 2M€ Cerrado

SAF2015-66690-R APROXIMACIONES BASADAS EN LA DIANA Y FENOTIPICAS PARA EL DES... 145K€ Cerrado

ASAAP-plus Clinical evaluation of AntimalarialS tri-therapy with AtovAq... 1M€ Cerrado

PID2021-127471OB-I00 HIBRIDOS DE INHIBIDORES DE TUBULINA Y DESACETILASAS PARA EL... 158K€ Cerrado

Duración del proyecto: 39 meses Fecha Inicio: 2023-03-07
Fecha Fin: 2026-06-30

Líder del proyecto

LABORATORIOS LICONSA Actividades propias de un laboratorio farmaceutico titular fabricante, comercializador exportador e importador de especialidades farmaceutic...

TRL 7-8 | 2M€

Presupuesto del proyecto 4M€

Descripción del proyecto Soil-Transmitted Helminths (STH) remain a significant public health problem with recognized obstacles for control and elimination with the current benzimidazole regimens in Mass Drug Administration (MDA) campaigns. Renewed targets from WHO for 2030 include elimination of STH morbidity in pre-school and school age children (PSAC & SAC), increased country governance and financial support and a strongyloidiasis control program; 2030 has also been targeted by WHO for controlling NTDs to attain the Sustainable Development Goals. The current proposal aims at accelerating the implementation of an innovative health technology, a fixed-dose combination (FDC) tablet of co-formulated albendazole and ivermectin, with adequate safety and significantly superior efficacy against T. trichiura in a registrational randomized clinical trial. This trial is being conducted in Ethiopia, Kenya and Mozambique with the guidance of EMA and sponsored by EDCTP (STOP projects) with a Phase II trial completed and a Phase III currently recruiting. This project, STOP2030, seeks to complement the results of the safety and efficacy trial with a field-based safety and effectiveness clinical study, acceptability studies in Ghana and Kenya, modelling and cost-effectiveness exercises. The resulting information will be consolidated to build a multidisciplinary package for policy making and WHO guidance with the support of advocacy and communication activities to reach stakeholders and maximize the exploitation and impact of the FDC for STH control and elimination. The Consortium assembled to execute the STOP2030 proposal combines expertise in complementary fields from program assessment and implementation through Ministries of Health in sub-Saharan African countries, advocacy, state of the art technology, leadership in clinical research and a pharma that has shown commitment for generating access to drugs against NTDs and has recently obtained WHO prequalification for generic ivermectin.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores